Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silence Therapeutics (SLN) Accounts Payables (2019 - 2025)

Silence Therapeutics' Accounts Payables history spans 7 years, with the latest figure at $13.4 million for Q4 2025.

  • For Q4 2025, Accounts Payables fell 18.56% year-over-year to $13.4 million; the TTM value through Dec 2025 reached $13.4 million, down 18.56%, while the annual FY2025 figure was $13.4 million, 18.56% down from the prior year.
  • Accounts Payables for Q4 2025 was $13.4 million at Silence Therapeutics, down from $17.0 million in the prior quarter.
  • Across five years, Accounts Payables topped out at $18.8 million in Q1 2025 and bottomed at $13.4 million in Q4 2025.
  • The 5-year median for Accounts Payables is $15.1 million (2023), against an average of $15.6 million.
  • The largest annual shift saw Accounts Payables soared 34.38% in 2021 before it fell 18.56% in 2025.
  • A 5-year view of Accounts Payables shows it stood at $14.5 million in 2021, then grew by 1.94% to $14.8 million in 2022, then grew by 4.11% to $15.4 million in 2023, then grew by 6.31% to $16.4 million in 2024, then dropped by 18.56% to $13.4 million in 2025.
  • Per Business Quant, the three most recent readings for SLN's Accounts Payables are $13.4 million (Q4 2025), $17.0 million (Q3 2025), and $14.3 million (Q2 2025).